Interleukin-5 Receptor Subunit Oligomerization and Rearrangement Revealed by Fluorescence Resonance Energy Transfer Imaging
Overview
Affiliations
Interleukin (IL)-5 exerts hematopoietic functions through binding to the IL-5 receptor subunits, alpha and betac. Specific assembly steps of full-length subunits as they occur in cell membranes, ultimately leading to receptor activation, are not well understood. We tracked the oligomerization of IL-5 receptor subunits using fluorescence resonance energy transfer (FRET) imaging. Full-length IL-5Ralpha and betac were expressed in Phoenix cells as chimeric proteins fused to enhanced cyan or yellow fluorescent protein (CFP or YFP, respectively). A time- and dose-dependent increase in FRET signal between IL-5Ralpha-CFP and betac-YFP was observed in response to IL-5, indicative of heteromeric receptor alpha-betac subunit interaction. This response was inhibited by AF17121, a peptide antagonist of IL-5Ralpha. Substantial FRET signals with betac-CFP and betac-YFP co-expressed in the absence of IL-5Ralpha demonstrated that betac subunits exist as preformed homo-oligomers. IL-5 had no effect on this betac-alone FRET signal. Interestingly, the addition of IL-5 to cells co-expressing betac-CFP, betac-YFP, and nontagged IL-5Ralpha led to further increase in FRET efficiency. Observation of preformed betac oligomers fits with the view that this form can lead to rapid cellular responses upon IL-5 stimulation. The IL-5-induced effects on betac assembly in the presence of nontagged IL-5Ralpha provide direct evidence that IL-5 can cause higher order rearrangements of betac homo-oligomers. These results suggest that IL-5 and perhaps other betac cytokines (IL-3 and granulocyte/macrophage colony-stimulating factor) trigger cellular responses by the sequential binding of cytokine ligand to the specificity receptor (subunit alpha), followed by binding of the ligand-subunit alpha complex to, and consequent rearrangement of, a ground state form of betac oligomers.
Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases.
Antosz K, Batko J, Blazejewska M, Gawor A, Sleziak J, Gomulka K Biomedicines. 2024; 12(7).
PMID: 39062104 PMC: 11275030. DOI: 10.3390/biomedicines12071531.
Bellon J, Birkholz O, Richter C, Eull F, Kenneweg H, Wilmes S Cell Rep Methods. 2022; 2(2):100165.
PMID: 35474965 PMC: 9017138. DOI: 10.1016/j.crmeth.2022.100165.
Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations.
Wilmes S, Hafer M, Vuorio J, Tucker J, Winkelmann H, Lochte S Science. 2020; 367(6478):643-652.
PMID: 32029621 PMC: 8117407. DOI: 10.1126/science.aaw3242.
Richter D, Moraga I, Winkelmann H, Birkholz O, Wilmes S, Schulte M Nat Commun. 2017; 8:15976.
PMID: 28706306 PMC: 5519985. DOI: 10.1038/ncomms15976.
Dynamic Modulation of Binding Affinity as a Mechanism for Regulating Interferon Signaling.
Li H, Sharma N, General I, Schreiber G, Bahar I J Mol Biol. 2017; 429(16):2571-2589.
PMID: 28648616 PMC: 5545807. DOI: 10.1016/j.jmb.2017.06.011.